Latest Breaking News On - Ivand horak - Page 1 : vimarsana.com
Tessa Therapeutics Announces Collaboration with A*STAR s
globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.
Tessa Therapeutics Announces Collaboration with A*STAR s Institute of Molecular and Cell Biology to Form Cell Therapy Laboratory, Business News
asiaone.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from asiaone.com Daily Mail and Mail on Sunday newspapers.
(1)
BEDMINSTER, N.J. and SINGAPORE, Feb. 10, 2021 /PRNewswire/
Tessa Therapeutics Ltd. (Tessa), a clinical-stage cell therapy company developing next-generation cancer treatments for hematological malignancies and solid tumors, today announced the successful completion of dosing of the first patient cohort (n=3) in a Phase I dose escalation study, evaluating the safety and efficacy of Tessa s TT11X - Allogeneic CD30-CAR Epstein Barr Virus Specific T-cell (EBVST) therapy.
The Phase 1 study being conducted at Baylor College of Medicine aims to enroll up to 18 patients with CD30+ lymphoma across three dose levels. Study objectives are to evaluate safety and efficacy and establish dosing for the next phase. TT11X has been administered to three patients so far at Houston Methodist Hospital with a favorable safety profile. The therapy has been well tolerated with no evidence of GVHD or any severe adverse events associated with allogeneic therapies,
Share this article
BEDMINSTER, N.J. and SINGAPORE, Jan. 18, 2021 /PRNewswire/
Tessa Therapeutics (Tessa), a clinical-stage cell therapy company developing next-generation cancer treatments for hematological malignancies and solid tumors, today announced that the European Medicines Agency (EMA) has granted PRiority MEdicines (PRIME) designation to the company s lead autologous CD30 CAR-T therapy for the treatment of relapsed or refractory classical Hodgkin Lymphoma (R/R cHL).
PRIME is a program launched by EMA to optimize development plans and speed up evaluation of medicines that demonstrate major therapeutic advantage over existing treatments, or otherwise benefit patients without treatment options. Through this program, EMA offers enhanced support to medicine developers including early interaction and dialogue, and a pathway for accelerated evaluation by the agency.